Descrizione

Viscosupplementation is the term that describes the use of intraarticular hyaluronates for the treatment of pain in osteoarthritic joints. Viscosupplementation is a highly used palliative treatment for knee OA because of ease of application and theoretical ability to relieve symptoms by restoring and replenishing hyaluronate component into the knee joint. The global viscosupplementation market in terms of revenue is set to grow by US$ 2 miliardi durante 2021-2027, crescendo ad un tasso di crescita annuale composto (CAGR) Di 8.7% durante il periodo di previsione, secondo la società di dati e analisi StrategyHelix. Growth in the geriatric population, increasing prevalence of knee osteoarthritis, rapid expansion of healthcare facilities in developing economies are expected to boost the market growth in the coming years.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2017-2020 e previsione a 2027 covering key market aspects like sales value for viscosupplementation. The global viscosupplementation market is segmented on the basis of product, applicazione, regione. Per prodotto, it is categorized into single-injection cycle, three-injection cycle, and five-injection cycle. The three-injection cycle segment held the largest market share in 2020. Per applicazione, the viscosupplementation market is divided into knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, e altri. The knee osteoarthritis segment accounted for the largest market share in 2020. Based on region, the viscosupplementation market is divided into North America, Asia Pacifico, Europa, and Rest of the World (ROW).

The report has profiled some of the key players of the market such as Altergon Italia Srl, Anika Therapeutics Inc., Bioventus LLC, Bloomage Freda Biopharm Co. Ltd., Chugai Pharmaceutical Co. Ltd., Contipro a.s., Ferring Pharmaceuticals AS, Fidia Farmaceutici S.p.A., Kewpie Corporation, Lifecore Biomedical Inc., Meiji Holdings Co. Ltd., Sanofi S.A., Seikagaku Corporation, Zimmer Biomet Holdings Inc..

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the viscosupplementation market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Prodotto: single-injection cycle, three-injection cycle, and five-injection cycle
Applicazione: knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, e altri
Regione: Nord America, Asia Pacifico, Europa, and Rest of the World (ROW)
Anni considerati: la presente relazione copre il periodo 2017 A 2027

Principali vantaggi per gli stakeholder

Get a comprehensive picture of the global viscosupplementation market
Individuare i settori in crescita e le tendenze per gli investimenti
Understand what the future of the global viscosupplementation market looks like
Identificare il panorama competitivo e la finestra di opportunità

Sommario

1. Definizione del mercato
2. Metodologia di ricerca
3. Dati di mercato & Veduta
3.1 Valore di mercato
3.2 Previsione del valore di mercato
4. Viscosupplementation Market by Product
4.1 Single-Injection Cycle
4.2 Three-Injection Cycle
4.3 Five-Injection Cycle
5. Viscosupplementation Market by Application
5.1 Knee Osteoarthritis
5.2 Hip Osteoarthritis
5.3 Shoulder Osteoarthritis
5.4 Altri
6. Viscosupplementation Market by Region
6.1 Nord America
6.2 Asia Pacifico
6.3 Europa
6.4 Rest Of The World (Row)
7. Profili aziendali
7.1 Altergon Italia Srl
7.2 Anika Therapeutics Inc.
7.3 Bioventus LLC
7.4 Bloomage Freda Biopharm Co., Ltd.
7.5 Chugai Pharmaceutical Co. Ltd.
7.6 Contipro a.s.
7.7 Ferring Pharmaceuticals AS
7.8 Fidia Farmaceutici S.p.A.
7.9 Kewpie Corporation
7.10 Lifecore Biomedical, Inc.
7.11 Meiji Holdings Co., Ltd.
7.12 Sanofi S.A.
7.13 Seikagaku Corporation
7.14 Zimmer Biomet Holdings, Inc.
8. Appendice
8.1 Informazioni su StrategyHelix
8.2 Disclaimer